Values as of: 2024-10-30
COMMON STOCK | Biotechnology |
Last Closing
USD 32.44Change
+3.71 (+12.91)%Market Cap
USD 8.08BVolume
6.74MAnalyst Target
USD 30.00Verdict
Verdict
Exelixis, Inc., an oncology company, focuses on the discovery, development, and commercialization of new medicines for difficult-to-treat cancers in the United States. The company offers CABOMETYX tablets for the treatment of patients with advanced renal cell carcinoma who received prior anti-angiogenic therapy; and COMETRIQ capsules for the treatment of progressive and metastatic medullary thyroid cancer. Its CABOMETYX and COMETRIQ are derived from cabozantinib, an inhibitor of multiple tyrosine kinases, including MET, AXL, RET, and VEGF receptors. The company also offers COTELLIC, an inhibitor of MEK as a combination regimen to treat specific forms of advanced melanoma; and MINNEBRO, an oral non-steroidal selective blocker of the mineralocorticoid receptor for the treatment of hypertension in Japan. It develops zanzalintinib, a novel, potent, next-generation oral tyrosine kinase inhibitor (TKI) that targets VEGF receptors, MET and the TAM kinases (TYRO3, AXL and MER); and XB002, a next-generation tissue factor (TF)-targeting ADC, administered via intravenous infusion and composed of a human monoclonal antibody (mAb) against TF that is conjugated to an auristatin-based microtubulin inhibitor (MTI) payload. It has research collaborations and license agreements with Ipsen Pharma SAS; Takeda Pharmaceutical Company Ltd.; F. Hoffmann-La Roche Ltd.; Redwood Bioscience, Inc.; R.P. Scherer Technologies, LLC; Catalent Pharma Solutions, Inc.; NBE Therapeutics AG; Aurigene Discovery Technologies Limited; Iconic Therapeutics, Inc.; Invenra, Inc.; StemSynergy Therapeutics, Inc.; Genentech, Inc.; Bristol-Myers Squibb Company; and Daiichi Sankyo Company, Limited, as well as clinical development agreement and collaboration with Sairopa B.V. and Merck & Co., Inc. The company was formerly known as Exelixis Pharmaceuticals, Inc. and changed its name to Exelixis, Inc. in February 2000. Exelixis, Inc. was incorporated in 1994 and is headquartered in Alameda, California.
Company Website : https://www.exelixis.com
Currency: USD
Country : USA
| Symbol | Name | Price(Change) | Market Cap |
|---|---|---|---|
| VRTX | Vertex Pharmaceuticals Inc |
+4.72 (+1.00%) |
USD 121.32B |
| REGN | Regeneron Pharmaceuticals Inc |
-4.54 (-0.49%) |
USD 103.77B |
| ALNY | Alnylam Pharmaceuticals Inc |
-3.20 (-1.12%) |
USD 36.83B |
| ARGX | argenx NV ADR |
-1.17 (-0.21%) |
USD 33.21B |
| BGNE | BeiGene Ltd |
-10.54 (-4.87%) |
USD 24.57B |
| MRNA | Moderna Inc |
-0.50 (-0.91%) |
USD 20.52B |
| RPRX | Royalty Pharma Plc |
+0.04 (+0.15%) |
USD 16.47B |
| UTHR | United Therapeutics Corporatio.. |
+8.60 (+2.44%) |
USD 15.69B |
| SMMT | Summit Therapeutics PLC |
-3.18 (-14.57%) |
USD 15.13B |
| PCVX | Vaxcyte Inc |
+0.55 (+0.52%) |
USD 13.95B |
| Symbol | Name | Weight | Mer | Price(Change) | Market Cap |
|---|---|---|---|---|---|
| IDNA | iShares Genomics Immunolo.. | 5.29 % | 0.00 % |
+0.08 (+0.38%) |
USD 0.14B |
| XDNA:CA | iShares Genomics Immunolo.. | 4.71 % | 0.00 % |
+0.03 (+0.38%) |
CAD 5.23M |
| FBT:LSE | First Trust Global Funds .. | 3.66 % | 0.00 % |
+19.60 (+0.38%) |
USD 8.17M |
| FBTU:LSE | First Trust Global Funds .. | 3.66 % | 0.00 % |
+0.27 (+0.38%) |
USD 8.17M |
| BBP | Virtus LifeSci Biotech Pr.. | 1.96 % | 0.79 % |
-0.56 (0.38%) |
USD 0.02B |
| LSEQ | Harbor ETF Trust | 1.90 % | 0.00 % |
+0.11 (+0.38%) |
USD 0.02B |
| JMEE | JPMorgan Market Expansion.. | 0.68 % | 0.00 % |
N/A |
USD 1.42B |
| LSAF | LeaderSharesTM AlphaFacto.. | 0.00 % | 0.75 % |
+0.03 (+0.38%) |
USD 0.16B |
| MUSC:CA | Manulife Multifactor U.S... | 0.00 % | 0.62 % |
+0.38 (+0.38%) |
CAD 3.66M |
| Market Performance vs. Industry/Classification (Biotechnology) | Market Performance vs. Exchange | ||||||
| Value | Sector Median | Percentile Rank | Grade | Market Median | Percentile Rank | Grade | |
| YTD | |||||||
| Capital Gain | 35.22% | 51% | F | 73% | C | ||
| Dividend Return | N/A | N/A | N/A | N/A | N/A | ||
| Total Return | 35.22% | 51% | F | 73% | C | ||
| Trailing 12 Months | |||||||
| Capital Gain | 54.33% | 50% | F | 71% | C- | ||
| Dividend Return | N/A | N/A | N/A | N/A | N/A | ||
| Total Return | 54.33% | 50% | F | 71% | C- | ||
| Trailing 5 Years | |||||||
| Capital Gain | 102.62% | 62% | D | 78% | C+ | ||
| Dividend Return | N/A | N/A | N/A | N/A | N/A | ||
| Total Return | 102.62% | 62% | D | 78% | C+ | ||
| Average Annual (5 Year Horizon) | |||||||
| Capital Gain | 4.68% | 54% | F | 54% | F | ||
| Dividend Return | 4.68% | 54% | F | 51% | F | ||
| Total Return | N/A | N/A | N/A | N/A | N/A | ||
| Risk Return Profile | |||||||
| Volatility (Standard Deviation) | 19.71% | 96% | N/A | 77% | C+ | ||
| Risk Adjusted Return | 23.77% | 80% | B- | 57% | F | ||
| Market Capitalization | 8.08B | 97% | N/A | 92% | A | ||
| Target Price Action | Rating Action | Analyst | Rating | Price | Date |
|---|
This is a composite scorecard based on the application of evaluation criteria deemed most important by analysts. This is not a buy or sell recommendation.
This stock has performed well, on a risk adjusted basis, compared to its sector peers(for a hold period of at least 12 months) and is in the top quartile.
The company management has delivered better return on assets in the most recent 4 quarters than its peers, placing it in the top quartile.
The company management has delivered better return on invested capital in the most recent 4 quarters than its peers, placing it in the top quartile.
The company management has delivered better return on equity in the most recent 4 quarters than its peers, placing it in the top quartile.
The stock’s annual returns have been stable and consistent compared to its sector peers(for a hold period of at least 12 months) and is in the top quartile. Although stability is good, also keep in mind it can limit returns.
This is one of the largest entities in its sector and is among the top quartile. Such companies tend to be more stable.
The company had positive total cash flow in the most recent four quarters.
The company had positive total free cash flow in the most recent four quarters.
This stock is in the top quartile compared to its peers on Gross Profit to Asset Ratio. This is a popular measure among value investors for showing superior returns in the long run.
The stock is trading high compared to its peers on a price to cash flow basis. It is priced above the median for its sectors. Proceed with caution if you are considering to buy.
The stock is trading high compared to its peers median on a price to book value basis.
The stock is trading high compared to its peers on a price to earning basis and is above the sector median.
The stock is trading high compared to its peers on a price to free cash flow basis. It is priced above the median for its sectors. Proceed with caution if you are considering to buy.
